Australia markets close in 1 hour 51 minutes

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.77+0.10 (+0.36%)
At close: 04:00PM EST
27.77 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close27.67
Bid27.84 x 800
Ask28.89 x 1100
Day's range27.75 - 28.26
52-week range26.32 - 42.99
Avg. volume655,913
Market cap18.968B
Beta (5Y monthly)0.79
PE ratio (TTM)28.93
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

    Company Announcement COPENHAGEN, Denmark; February 29, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in

  • GlobeNewswire

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00,19,631 shares at DKK 1,032.00,2,473 shares at DKK 1,050.00,1,422 shares at DKK 1,

  • Business Wire

    U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

    COPENHAGEN, Denmark, February 27, 2024--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.